Abstract
Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, associated with indolent clinical courses and favorable outcomes. Here, we considered 85 recipients of UCB allo-HSCT to more broadly define the impact of lymphocytosis, not limited to LGL. Sustained lymphocytosis was observed in 21 (25%) patients at a median onset of 12.6 months and with a median duration of 12 months. Immunophenotypic analysis showed predominantly CD8+ T and/or polyclonal B-cell expansions. Three patients only had monoclonal T-cell expansion. CMV reactivation was significantly more frequent in the group of patients with lymphocytosis (76% vs 28%, P=0.0001), but was not associated with survival. Conversely, 2-year disease-free survival and overall survival were significantly higher for lymphocytosis patients (85% vs 55%, P=0.01 and 85% vs 63%, P=0.03, respectively). In conclusion, expansion of T or B lymphocytes after UCB allo-HSCT in adults is not a rare event. Although occurring relatively late after transplant, this feature is predictive of a better outcome for the patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002; 99: 4610–4617.
Mohty M, Faucher C, Vey N, Chabannon C, Sainty D, Arnoulet C et al. Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. Leukemia 2002; 16: 2129–2133.
Nann-Rütti S, Tzankov A, Cantoni N, Halter J, Heim D, Tsakiris D et al. Large granular lymphocyte expansion after allogeneic hematopoietic stem cell transplant is associated with a cytomegalovirus reactivation and shows an indolent outcome. Biol Blood Marrow Transplant 2012; 18: 1765–1770.
Kim D, Al-Dawsari G, Chang H, Panzarella T, Gupta V, Kuruvilla J et al. Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT. Bone Marrow Transplant 2013; 48: 1104–1111.
Troussard X, Vol S, Cornet E, Bardet V, Couaillac JP, Fossat C et al. Full blood count normal reference values for adults in France. J Clin Pathol 2014; 67: 341–344.
Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618–4625.
van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317.
Lamy T, Loughran TP Jr . Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003; 40: 185–195.
Chang H, Kamel-Reid S, Hussain N, Lipton J, Messner HA . Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. Am J Clin Pathol 2005; 123: 196–199.
Acar K, Akı SZ, Ozkurt ZN, Bozdayı G, Rota S, Türköz Sucak G . Factors associated with cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation: human leukocyte antigens might be among the risk factors. Turk J Haematol 2014; 31: 276–285.
Carroll MC, Prodeus AP . Linkages of innate and adaptive immunity. Curr Opin Immunol 1998; 10: 36–40.
Lönnqvist B, Ringdèn O, Ljungman P, Wahren B, Gahrton G . Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986; 63: 671–679.
Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118: 1402–1412.
Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013; 122: 1316–1324.
Ito S, Pophali P, CO W, Koklanaris EK, Superata J, Fahle GA et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 2013; 48: 1313–1316.
Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ . Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009; 15: 54–60.
Haynes LD, Waldman WJ, Bushkin Y, Love RB, Burlingham WJ . CMV-infected allogeneic endothelial cells initiate responder and bystander donor HLA class I release via the metalloproteinase cleavage pathway. Hum Immunol 2005; 66: 211–221.
Daguindau E, Lioure B, Buzyn A, Robin M, Faucher C, Kuentz M et al. Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment. Bone Marrow Transplant 2010; 45: 177–180.
Wallet HL, Sobh M, Morisset S, Robin M, Fegueux N, Fürst S et al. Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. Exp Hematol 2013; 41: 924–933.
Rio B, Chevret S, Vigouroux S, Chevallier P, Fürst S et alSociété Française de Greffe de Moelle et de Thérapie Cellulaire and Eurocord. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biol Blood Marrow Transplant 2015; 21: 445–453.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Le Bris, Y., Guillaume, T., Ménard, A. et al. Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults. Bone Marrow Transplant 52, 854–858 (2017). https://doi.org/10.1038/bmt.2016.364
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.364